logo-loader
viewCytoDyn Inc.

CytoDyn armed with 'key test' to guide its near-term discussions with the FDA

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the late-stage biotechnology company developing leronlimab (PRO 140) as a monotherapy for HIV patients has completed a key test will would “guide” discussions with the FDA on leronlimab as a single treatment for HIV.

Dr. Pourhassan says the company has completed a diagnostic test, called a Receptor Occupancy Test, as a measure for more precise screening for leronlimab monotherapy.

Quick facts: CytoDyn Inc.

Price: 1.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $467.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals more promising results from its clinical...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company has revealed additional “promising results” from its clinical trials evaluating its lead drug leronlimab for the treatment of metastatic triple-negative breast cancer and metastatic breast...

4 days, 20 hours ago

2 min read